All tags Primary Antibodies A better CD31 antibody

A better CD31 antibody

We asked an independent collaborator to test our anti-CD31 rabbit monoclonal against the leading competitors.

The anti-CD31 antibody is commonly used in angiogenesis research and work that requires the identification of endothelium by immunohistochemistry (IHC). Using human and mouse kidney samples, we asked an independent collaborator to compare our anti-CD31 RabMAb® rabbit monoclonal (ab76533) against the leading monoclonal alternatives.

Results

Our anti-CD31 antibody outperformed the competition:

  • It is more specific than both competitors in human tissue, giving you accurate results with low background
  • It can be used at up to an eight-times lower concentration that competitor antibodies, saving you valuable reagents


Human tissue

Citric acid antigen retrieval method

Abcam anti-CD31 (ab76533)Competitor XCompetitor Y
1/400 dilution1/50 dilution1/50 dilution


Tris-EDTA antigen retrieval method

Abcam anti-CD31 (ab76533)Competitor XCompetitor Y
1/200 dilution1/50 dilution1/50 dilution


Testing conditions

A series of dilutions was conducted to determine the optimal concentration of each primary antibody. The secondary antibodies were biotinylated and used at a 1/300 dilution. Blocking solution was 2% BSA in 1x TBS and azide (pH7.6). Optimal antigen retrieval methods were found to be tris-EDTA (pH9) or citric acid (pH6).

Try our anti-CD31 RabMAb® rabbit monoclonal (ab76533) in a 10 µL trial size






Sign up